In another study, simultaneous targeting of Src kinase and receptor tyrosine kinase with saracatinib and sunitinib resulted in up to 80% blockade of RCC cell migration, synergistic inhibition of cell growth and reduction of acquired drug resistance [23]. Here, NTRK1 is linked to renal cell adenocarcinoma.